PaxMedica Inc

PaxMedica, Inc. is an early clinical stage biopharmaceutical company. It focuses on the development of anti-purinergic therapies for the treatment of neurodevelopmental disorders, including autism spectrum disorder and Fragile X syndrome tremor-ataxia. The company was founded in April 5, 2018 and is headquartered in Woodcliff Lake, NJ.

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q3 2024

Earnings data Q1 2024

Earnings data Q4 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

PaxMedica, Inc. is a clinical stage biopharmaceutical company. It engages in the business of developing drug candidates for the treatment of autism spectrum disorder, Fragile X syndrome tremor-ataxia, and Human African Trypanosomiasis. The company was founded by Michael L. Derby on April 5, 2018 and is headquartered in Tarrytown, NY.

IPO season continues today with another exciting entrant. PaxMedica (NASDAQ: PXMD ) is the newest company to make its public debut.

Is PaxMedica (PXMD) Stock the Next Hot IPO?

Shares will Trade on Nasdaq Capital Market under Ticker Symbol "PXMD" TARRYTOWN, NY / ACCESSWIRE / August 26, 2022 / PaxMedica, Inc. (Nasdaq:PXMD), a clinical stage biopharmaceutical company focusing on the development of anti-purinergic drug therapies for the treatment of disorders with intractable neurologic symptoms, today announced the pricing of its initial public offering of 1,545,454 shares of its common stock at a public price of $5.25 per share. The gross proceeds to PaxMedica from the offering, before deducting underwriting discounts, commissions and offering expenses, are expected to be approximately $8.1 million.

Craft Capital Management Announces Pricing of Initial Public Offering for PaxMedica, Inc.

Shares will Trade on Nasdaq Capital Market under Ticker Symbol “PXMD”

PaxMedica, Inc. Announces Pricing of Initial Public Offering

News for PaxMedica Inc Stock (PXMD)